Cargando…

Efficacy of Lamivudine or Entecavir against Virological Rebound after Achieving HBV DNA Negativity in Chronic Hepatitis B Patients

Nucleos(t)ide analogues (NAs) lead to viral suppression and undetectable hepatitis B virus (HBV) DNA in some individuals infected with HBV, but the rate of virological rebound has been unknown in such patients. We examined the prevalence of virological rebound of HBV DNA among NA-treated patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miyauchi, Tomoo, Kanda, Tatsuo, Shinozaki, Masami, Kamezaki, Hidehiro, Wu, Shuang, Nakamoto, Shingo, Kato, Kazuki, Arai, Makoto, Mikami, Shigeru, Sugiura, Nobuyuki, Kimura, Michio, Goto, Nobuaki, Imazeki, Fumio, Yokosuka, Osamu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2013
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619113/ https://www.ncbi.nlm.nih.gov/pubmed/23569428 http://dx.doi.org/10.7150/ijms.5904

Ejemplares similares

Efficacy of Lamivudine or Entecavir on Acute Exacerbation of Chronic Hepatitis B
por: Kanda, Tatsuo, et al.
Publicado: (2011)

Adherence to Medication Is a More Important Contributor to Viral Breakthrough in Chronic Hepatitis B Patients Treated with Entecavir Than in Those with Lamivudine
por: Kamezaki, Hidehiro, et al.
Publicado: (2013)

Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus Ribavirin
por: Kanda, Tatsuo, et al.
Publicado: (2016)

Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine
por: Yasutake, Yoshiaki, et al.
Publicado: (2020)

Entecavir and lamivudine therapy for severe acute chronic hepatitis B
por: LIU, CHANGHONG, et al.
Publicado: (2013)

Hepatic STAT1-Nuclear Translocation and Interleukin 28B Polymorphisms Predict Treatment Outcomes in Hepatitis C Virus Genotype 1-Infected Patients
por: Miyamura, Tatsuo, et al.
Publicado: (2011)

The Comparative Efficacy and Safety of Entecavir and Lamivudine in Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis
por: Yang, Jiao, et al.
Publicado: (2016)

Pegylated interferon-alfa-2a monotherapy in patients infected with HCV genotype 2 and importance of rapid virological response
por: Etoh, Reiko, et al.
Publicado: (2011)

Sustained Virological Response after 8-Week Treatment of Simeprevir with Peginterferon α-2a plus Ribavirin in a Japanese Female with Hepatitis C Virus Genotype 1b and IL28B Minor Genotype
por: Kanda, Tatsuo, et al.
Publicado: (2015)

Involvement of multidrug resistance protein 4 in the hepatocyte efflux of lamivudine and entecavir
por: Liu, Yu-Tian, et al.
Publicado: (2018)

Emergence of Lamivudine-Resistant HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV and HBV in China
por: Gu, Lijun, et al.
Publicado: (2015)

Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B
por: Song, Joon Chang, et al.
Publicado: (2011)

On-treatment HBV DNA dynamics predict virological breakthrough in entecavir-treated HBeAg-positive chronic hepatitis B
por: Huang, Yi-Jie, et al.
Publicado: (2017)

Lamivudine and Entecavir for Acute Hepatitis B: A Systematic Review and Meta-Analysis
por: Henriquez-Camacho, Cesar, et al.
Publicado: (2023)

De novo entecavir+adefovir dipivoxil+lamivudine triple-resistance mutations resulting from sequential therapy with adefovir dipivoxil, and lamivudine
por: Yang, Song, et al.
Publicado: (2016)

Is increasing the dose of Entecavir effective in partial virological responders?
por: Erturk, Ayse, et al.
Publicado: (2014)

Lamivudine treatment for severe acute HBV hepatitis
por: Lisotti, Andrea, et al.
Publicado: (2008)

Comparative Effectiveness of Lamivudine versus Entecavir in Patients with Hepatocellular Carcinoma: Watch out for Confounders!
por: Kim, Hwi Young
Publicado: (2016)

Lamivudine versus Entecavir for Newly Diagnosed Hepatitis B Virus-Related Hepatocellular Carcinoma
por: Kim, Jung Hee, et al.
Publicado: (2016)

Roles of ITPA and IL28B Genotypes in Chronic Hepatitis C Patients Treated with Peginterferon Plus Ribavirin
por: Miyamura, Tatsuo, et al.
Publicado: (2012)

HBV Core Protein Enhances Cytokine Production
por: Kanda, Tatsuo, et al.
Publicado: (2015)

Analysis of 5′ Nontranslated Region of Hepatitis A Viral RNA Genotype I from South Korea: Comparison with Disease Severities
por: Kanda, Tatsuo, et al.
Publicado: (2010)

Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy
por: Park, Jung Gil, et al.
Publicado: (2015)

Virologic, serologic, and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-naïve Chinese patients with chronic hepatitis B: a randomized, multicenter study
por: Yao, Guangbi, et al.
Publicado: (2008)

Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis
por: Sheng, Yun-Jian, et al.
Publicado: (2011)

Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir
por: Ze, EunYoung, et al.
Publicado: (2014)

Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment
por: Kim, Hong Joo, et al.
Publicado: (2016)

HIV-1 with HBV-associated Q151M substitution in RT becomes highly susceptible to entecavir: structural insights into HBV-RT inhibition by entecavir
por: Yasutake, Yoshiaki, et al.
Publicado: (2018)

The role of lamivudine versus entecavir in prevention of HCC in patients with hepatitis B virus-related cirrhosis
por: Olariu, Cristina, et al.
Publicado: (2013)

Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir
por: Jeon, Hee-Jeong, et al.
Publicado: (2017)

Renal safety of tenofovir and/or entecavir in patients with chronic HBV monoinfection
por: Yang, Young-Mo, et al.
Publicado: (2017)

Acute Liver Injury in a Patient with Alcohol Dependence: A Case Resembling Autoimmune Hepatitis or Drug-Induced Liver Injury
por: Hayashi, Masahiro, et al.
Publicado: (2014)

Occurrence and Recurrence of Hepatocellular Carcinoma Were Not Rare Events during Phlebotomy in Older Hepatitis C Virus-Infected Patients
por: Kanda, Tatsuo, et al.
Publicado: (2014)

Effect of Hepatitis C Virus Genotype 1b Core and NS5A Mutations on Response to Peginterferon Plus Ribavirin Combination Therapy
por: Nakamoto, Shingo, et al.
Publicado: (2015)

HBV quasispecies composition in Lamivudine-failed chronic hepatitis B patients and its influence on virological response to Tenofovir-based rescue therapy
por: Banerjee, Priyanka, et al.
Publicado: (2017)

Discrepancy between Hepatitis C Virus Genotypes and NS4-Based Serotypes: Association with Their Subgenomic Sequences
por: Win, Nan Nwe, et al.
Publicado: (2017)

Laboratory Evaluation of Three Regimens of Treatment of Chronic Hepatitis B: Tenofovir, Entecavir and Combination of Lamivudine and Adefovir
por: Jayakumar, Rajeswari, et al.
Publicado: (2012)

Impact of prior lamivudine use on the antiviral efficacy and development of resistance to entecavir in chronic hepatitis B patients
por: Hwang, Joo An, et al.
Publicado: (2015)

Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance
por: Wang, Guiliang, et al.
Publicado: (2015)

Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response
por: Woo, Hyun Young, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_10jiu64a66n4l8her73fhd6e4e